Key Takeaways BMY will halt the phase III Librexia ACS trial after milvexian missed efficacy expectations.IDMC advised continuing Librexia AF and Librexia STROKE, with data expected in 2026.The setback hits BMY's cardiovascular ambitions, which include Camzyos and EliquisBristol Myers Squibb (BMY) recently announced that it will discontinue the late-stage Librexia study on cardiovascular candidate milvexian, an investigational oral, highly selective factor XIa (FXIa) inhibitor.BMY and partner Johnson & John ...